FOXO4-DRI
FOXO4-DRI, also written FOXO4 DRI, is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our longevity category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | FOXO4-DRI |
|---|---|
| Also known as | Proxofim, FOXO4-D-Retro-Inverso |
| Synonyms | Proxofim, FOXO4-D-Retro-Inverso |
| Classification | Senolytic peptide, FOXO4-p53 interaction blocker |
| Peptide type | Synthetic D-retro-inverso peptide |
| CAS number | 2460055-10-9 |
| Molecular formula | C228H388N86O64 |
| Molecular weight | Approximately 5358.15 g/mol (free base) |
| Structure | D-retro-inverso peptide comprising part of the p53-interaction domain of FOXO4, with a reversed amino acid sequence and D-amino acid substitutions for resistance to enzymatic degradation |
| Purity | ≥98% (HPLC-verified, batch-by-batch) |
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 10 mg. Pre-filled pens: 10 mg |
| Reconstitution | Reconstitute using bacteriostatic water or sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct light. For long-term storage prior to reconstitution, freezing conditions are recommended. Storage conditions are confirmed on the Certificate of Analysis supplied with each order. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-09-02. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The work is a senolytic story told entirely in animals and cells. Studies have examined selective removal of senescent cells, and in aged mice a reported normalisation of weight loss, hair loss and kyphosis with increased muscle mass and fitness, and separately an effect on age-related testosterone secretion by targeting senescent Leydig cells. The design concept, a retro-inverso peptide built to disrupt a specific protein interaction, is itself the subject of patent filings.
What is not established
Any human data. No clinical trial was identified in this review, so there is no human dose, no human safety profile and no evidence that selective removal of senescent cells behaves in a person as it does in an aged mouse. The mouse results are striking, and striking mouse results in ageing research have a long history of not transferring.
What distinguishes FOXO4-DRI
It is the clearest case in the catalogue of a compound whose entire appeal rests on a single animal result that reads like a headline. That is not a reason to avoid it and it is a reason to state where the evidence stops, because nothing else on this page can be said about it in a person.
Sources
- Senolytic peptide FOXO4-DRI selectively removes senescent cells
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
- Anti-senescence compounds and uses thereof, US patent 11723947
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
FOXO4-DRI in supply terms
FOXO4-DRI, also listed under the name Proxofim or by its full designation FOXO4-D-Retro-Inverso, is a synthetic peptide built using retro-inverso chemistry: the amino acid sequence is reversed end to end and substituted with D-amino acids in place of the natural L-form. This modification is a structural technique used to change how a peptide chain is read by proteolytic enzymes, and it is why the compound carries a five-figure molecular weight, approximately 5358.15 g/mol, well above most peptides on this list. The molecular formula is C228H388N86O64, and it is registered under CAS 2460055-10-9. The sequence corresponds to a region of the FOXO4 protein associated with a specific protein-interaction domain, reproduced here in reversed, D-substituted form. It sits in the Longevity category on this catalogue, grouped by the research literature associated with cellular senescence pathways, a categorisation convention rather than a claim about the compound. It is supplied as a lyophilised powder in multi-dose vials, typically at a 5mg fill weight, reconstituted with bacteriostatic water or sterile laboratory-grade water. Store at 2-8C away from direct light, with freezing recommended for extended storage. Given the high molecular weight and correspondingly high per-milligram synthesis cost, buyers should request full HPLC and mass spectrometry data on the Certificate of Analysis before comparing quotes across vendors.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for FOXO4-DRI and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Longevity
| Compound | Identifier | Presentation |
|---|---|---|
| 5-Amino-1MQ | 42464-96-0 (commonly supplied a... | Vials: 50 mg. Pre-filled pens: ... |
| Epithalon | C14H22N4O9 | Vials: 10 mg. Pre-filled pens: ... |
| MOTS-c | C101H152N28O22S2 | Vials: 10 mg. Pre-filled pens: ... |
| NAD+ | C21H27N7O14P2 | Vials: 500 mg. Pre-filled pens:... |
| SS-31 | C32H49N9O5 | Vials: 10 mg |
| Thymosin Alpha-1 (TA) | 62304-98-7 | Vials: 5 mg, 10 mg. Pre-filled ... |
Questions
Supply, answered
Is FOXO4-DRI available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy FOXO4-DRI. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply FOXO4-DRI as a second source?
Yes. Terms are agreed per compound, so you can add FOXO4-DRI without moving anything else you buy elsewhere.
Request pricing for FOXO4-DRI
Indicative volume and delivery country is enough to start. We reply within one working day.